OncoC4 Locks in $50 Million Series B to Advance Cancer Drug Pipeline

OncoC4 has secured nearly $50 million in fresh funding, closing its Series B round with GBA Fund at the helm and strong participation from existing backers HM Capital, 3E Bioventures Capital, Kaitai Capital, along with contributions from the company’s co-founders.

The investment marks a major push for the Rockville-based biotech as it ramps up clinical programs targeting cancer and neurodegenerative diseases.

Founded in 2020 by immunologists Dr. Yang Liu and Dr. Pan Zheng, the company has built a pipeline aimed at delivering therapies with first-in-class or best-in-class potential.

The new capital will largely be used to accelerate trials already in progress and bring additional candidates forward.

“Our Series B financing round progressed rapidly, and we deeply appreciate our investors' recognition of our Company and continual support,” said Dr. Yang Liu, Co-Founder, Chairman, CEO and CSO of OncoC4, emphasizing the company’s plans to expand both development and business operations worldwide.

The financing comes at a time when biotech fundraising has tightened, with many early-stage companies struggling to attract sizable backing.

In that context, OncoC4’s $50 million round signals strong investor confidence in its approach to immuno-oncology and translational medicine.

Industry watchers have noted that momentum in cancer therapeutics remains high, with new checkpoint inhibitors and targeted biologics continuing to draw investment even as broader biotech markets face volatility.

By channeling its funding into advancing its core drug candidates, OncoC4 positions itself among a small group of young biotech firms that have managed to push forward clinical programs while maintaining strong support from early investors.